Trial Profile
A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary)
- Indications Erythrodermic psoriasis; Pustular psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 03 Oct 2018 Planned End Date changed from 21 Sep 2018 to 30 Nov 2018.
- 07 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Aug 2018.